Presence of the full-length KIR2DS4 gene reduces the chance of rheumatoid arthritis patients to respond to methotrexate treatment

BMC Musculoskeletal Disorders

Piotr Kuśnierczyk³  Daria Gendosz³  Andrzej Pawlik²  Edyta Majorczyk¹ 

[1] Biochemistry and Physiology, Institute of Physiotherapy, Faculty of Physical Education and Physiotherapy, Opole University of Technology, Proszkowska 76, 45-758 Opole, Poland;Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian University of Medicine, Powstańców Wlkp. 72, 70-111 Szczecin, Poland;Laboratory of Immunogenetics and Tissue Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wrocław, Poland

关键词: KIR ligand;    KIR;    Methotrexate;    Treatment response;    Rheumatoid arthritis;   

Others  :  1122290
DOI  :  10.1186/1471-2474-15-256

 received in 2013-08-26, accepted in 2014-06-30,  发布年份 2014

【 摘 要 】

Background

KIR genes coding for natural killer cell immunoglobulin-like receptors, KIR, influence the effector and regulatory function of NK cells as well as some subpopulations of T lymphocytes (e.g. CD4+CD28-KIR+) depending on presence of ligands (particularly HLA-C molecules). KIR-KIR ligand interaction may lead to the development of autoimmune disorders, including rheumatoid arthritis (RA). However, their role in the response of RA patients to methotrexate therapy is not known.

Methods

KIR genes and KIR-ligand (HLA-C C1/C2 allomorphs) genotyping was performed using the PCR-SSP method in 312 RA patients (179 classified as good responders and 133 as poor responders using DAS28 criteria). Thus, we evaluated the association of KIR genes and HLA-C allomorphs with the response to methotrexate (MTX) treatment.

Results

We observed that patients possessing the full-length KIR2DS4 (KIR2DS4f) gene had a lower chance of responding in comparison to KIR2DS4f-negative cases. This phenomenon was observed both in erosive disease (ED) and rheumatoid factor (RF) positive and in ED- and RF-negative patients. Interestingly, the observed effect of the KIR2DS4f gene was strongest in individuals possessing medium values (20-33 mm/h) of the erythrocyte sedimentation rate (ESR). Patients with high ESR values had low probability and, in contrast, patients with low ESR had a high probability of MTX response, and the presence of KIR2DS4f did not affect their outcome. Additionally, we show that the KIR2DS4f effect did not depend on the presence of either C1 or C2 allomorphs.

Conclusion

Our results suggest that the response of RA patients with medium ESR values to MTX treatment may be dependent on the full-length KIR2DS4 gene.

【 授权许可】

   
2014 Majorczyk et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jacob N, Jacob CO: Genetics of rheumatoid arthritis: an impressionist perspective. Rheum Dis Clin North Am 2012, 38:243-257.
• [2]Falgarone G, Jaen O, Boissier MC: Role for innate immunity in rheumatoid arthritis. Joint Bone Spine 2005, 72:17-25.
• [3]Tian Z, Gershwin ME, Zhang C: Regulatory NK cells in autoimmune response. J Autoimm 2012, 39:206-215.
• [4]Namekawa T, Snyder MR, Yen J-H, Goehring BE, Leibson PJ, Weyand CM, Goronzy JJ: Killer cell activating receptors function as costimulatory molecules on CD4 + CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol 2000, 165:1138-1145.
• [5]Parham P: MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005, 5:201-214.
• [6]Rajalingam R: Human diversity of killer cell immunoglobulin-like receptors and disease. Korean J Hematol 2011, 46:216-228.
• [7]Cooley S, Wesdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS: Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
• [8]Yokoyama WM: Inhibitory receptors signal activation. Immunity 2008, 29:515-517.
• [9]Raulet DH, Vance RE, McMahon CW: Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001, 19:291-330.
• [10]Kuśnierczyk P: Killer cell immunoglobulin-like receptor gene associations with autoimmune and allergic diseases, recurrent spontaneous abortion, and neoplasms. Front Immunol 2013. doi:10.3389/fimmu.2013.00008
• [11]Cauli A, Shaw J, Giles J, Hatano H, Rysnik O, Payeli S, McHugh K, Dessole G, Porru G, Desogus E, Fiedler S, Hölper S, Carette A, Blanco-Gelaz MA, Vacca A, Piga M, Ibba V, Garau P, La Nasa G, López-Larrea C, Mathieu A, Renner C, Bowness P, Kollnberger S: The arthritis-associated HLA-B*27:05 allele forms more cell surface B27 dimer and free heavy chain ligands for KIR3DL2 than HLAB*27:09. Rheumatology 2013, 52:1952-1962.
• [12]Kuśnierczyk P, Majorczyk E: Pas de quatre: an interaction of HLA-B*2705 and KIR3DL2 homodimers in spondyloarthropathies. Rheumatology 2013, 52:1931-1932.
• [13]McGeough CM, Berrar D, Wright G, Mathews C, Gilmore P, Cunningham RT, Bjourson AJ: Killer immunoglobulin-like receptor and human leukocyte antigen-C genotypes in rheumatoid arthritis primary responders and non-responders to anti-TNF-α therapy. Rheumatol Int 2012, 32:1647-1653.
• [14]Cronstein BN: Going with the flow: methotrexate, adenosine, and blood flow. Ann Rheum Dis 2006, 65:421-422.
• [15]Capone D, Spanò A, Gentile A, Ferrara G, Itto E, Palmiero G, Basile V, Oriente P: Are there differences in methotrexate kinetics between responding and nonresponding patients with rheumatoid arthritis? BioDrugs 2000, 13:373-379.
• [16]Marchesoni A, Battafarano N, Arreghini M, Panni B, Gallazzi M, Tosi S: Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 2003, 42:1545-1549.
• [17]Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, Kremer J: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004, 50:2766-2774.
• [18]Maillefert JF, Puéchal X, Falgarone G, Lizard G, Ornetti P, Solau E, Legré V, Lioté F, Sibilia J, Morel J, Maynadié M, Réseau Rhumato Study Group: Prediction of response to disease modifying antirheumatic drugs in rheumatoid arthritis. Joint Bone Spine 2010, 77:558-563.
• [19]Aslibekyan S, Brown EE, Reynolds RJ, Redden DT, Morgan S, Baggott JE, Sha J, Moreland LW, O'Dell JR, Curtis JR, Mikuls TR, Bridges SL Jr, Arnett DK: Genetic variants associated with methotrexate efficacy and toxicity in early rheumatoid arthritis: results from the treatment of early aggressive rheumatoid arthritis trial. Pharmacogenomics J 2014, 14:48-53.
• [20]Owen SA, Hider SL, Martin P, Bruce IN, Barton A, Thomson W: Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J 2013, 13:227-234.
• [21]Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993, 3:729-740.
• [22]Fuchs HA, Brooks RH, Callahan LF, Pincus T: A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989, 32:531-537.
• [23]Majorczyk E, Pawlik A, Łuszczek W, Nowak I, Wiśniewski A, Jasek M, Kuśnierczyk P: Associations of killer cell immunoglobulin-like receptor genes with complications of rheumatoid arthritis. Genes Immun 2007, 8:678-683.
• [24]Frohn C, Schlenke P, Ebel B, Dannenberg C, Bein G, Kitchner H: DNA typing for natural killer cell inhibiting HLA-Cw groups NK1 and NK2 by PCR-SSP. J Immunol Meth 1998, 218:155-160.
• [25]Excoffier L, Slatkin M: Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995, 12:921-927.
• [26]Téo FH, de Oliveira RT, Mamoni RL, Ferreira MC, Nadruz W Jr, Coelho OR, Fernandes Jde L, Blotta MH: Characterization of CD4 + CD28null T cells in patients with coronary artery disease and individuals with risk factors for atherosclerosis. Cell Immunol 2013, 281:11-19.
• [27]Niccoli G, Apa R, Lanzone A, Liuzzo G, Spaziani C, Sagnella F, Cosentino N, Moro F, Martinez D, Morciano A, Bacà M, Pazzano V, Gangale MF, Tropea A, Crea F: CD4 + CD28 null T lymphocytes are expanded in young women with polycystic ovary syndrome. Fertil Steril 2011, 95:2651-2654.
• [28]Pinto-Medel MJ, García-León JA, Oliver-Martos B, López-Gómez C, Luque G, Arnáiz-Urrutia C, Orpez T, Marín-Bañasco C, Fernández O, Leyva L: The CD4+ T-cell subset lacking expression of the CD28 costimulatory molecule is expanded and shows a higher activation state in multiple sclerosis. J Neuroimmunol 2012, 243:1-11.
• [29]Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, Gawrońska-Szklarz B: The expansion of CD4 + CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther 2003, 5:R210-R213.
• [30]Smoleńska Ż, Pawłowska J, Daca A, Soroczyńska-Cybula M, Witkowski J, Bryl EM: Disease activity in patients with long-lasting rheumatoid arthritis is associated with changes in peripheral blood lymphocyte subpopulations. Pol Arch Med Wewn 2012, 122:591-598.
• [31]van Bergen J, Thompson A, van der Slik A, Ottenhoff THM, Gussekloo J, Koning F: Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J Immunol 2004, 173:6719-6726.
• [32]Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, Goronzy JJ: Major histocompatibility complex class I-recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med 2001, 193:1159-1167.
• [33]Nowak I, Magott-Procelewska M, Kowal A, Miazga M, Wagner M, Niepiekło-Miniewska W, Kamińska M, Wiśniewski A, Majorczyk E, Klinger M, Łuszczek W, Pawlik A, Płoski R, Barcz E, Senitzer D, Kuśnierczyk P: Killer immunoglobulin-like receptor (KIR) and HLA genotypes affect the outcome of allogeneic kidney transplantation. PLoS One 2012, 7:e44718.
• [34]Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR: Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acids Res 2011, 39:D913-D919.
• [35]Middleton D, Gonzalez A, Gilmore PM: Studies on the expression of the deleted KIR2DS4*003 gene product and distribution of KIR2DS4 deleted and nondeleted versions in different populations. Hum Immunol 2007, 68:128-134.
• [36]Yen JH, Lin CH, Tsai WC, Wu CC, Ou TT, Hu CJ, Liu HW: Killer cell immunoglobulin-like receptor gene’s repertoire in rheumatoid arthritis. Scand J Rheumatol 2006, 35:124-127.
• [37]Romão VC, Canhão H, Fonseca JE: Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Medicine 2013, 11:17.